

Backgrounder


| Beta Cell Proliferation

Beta Cell Proliferation

- Natural Occurrences of Proliferation


Backgrounder – Beta Cell Proliferation

Natural History of Types 2 Diabetes – A Progressive Decline in Beta Cell Function




Kendall, D. Am J Med. 2009;122:S37.

Key Historic Findings Support the Presence of Beta-Cell Defects in T2D



Maclean and Ogilvie, *Diabetes* 4;1955


Reduced beta cell volume in T2D




Beta cell mass/function decline with increasing year since diagnosis

Recent Concepts Have Shown Beta Cell Failure is Essential for Development of T2D

Traditional View




Recent concepts



β -cell failure is essential (*sine qua non*)
for development of T2D

Backgrounder – Beta Cell Proliferation


Beta Cell Compensation in Physiological and Pathophysiological States in Mammals



Adapted from Science 2005

Background – Beta Cell Proliferation

Loss of Beta Cell Mass Drives the Progression of Type 1 and Type 2 Diabetes



Normal Glucose Tolerance (NGT) followed by Impaired Glucose Tolerance (IGT) followed by Type 2 Diabetes Mellitus (T2DM).

Insulin Resistance leads to an increase in Beta Cell Workload which ultimately leads to Beta Cell Failure and Death and the Progression of Type 2 Diabetes.

*Int. J. Mol. Sci. 2016, 17, 744; doi:10.3390/ijms17050744

Concepts of the Pathogenesis of Type 1 and Type 2 Diabetes

Prior Paradigm

Type 1 diabetes
β cell destruction
β cell mass ↓
Insulin secretion ↓

Type 2 diabetes
Obesity
Insulin resistance
Hyperinsulinemia

Current Paradigm

Type 1 diabetes
β cell destruction
β cell mass ↓
Insulin secretion ↓

Type 2 diabetes
β cell loss
β cell mass ↓
Insulin secretion ↓

Causes


Autoimmune

Insulin resistance
β cell overwork


Type 1 and Type 2 Diabetes results in
Loss of Beta Cell Mass

Background – Beta Cell Proliferation

Beta Cells Can Adapt to Metabolic Demand during Puberty



Tanner stages / sexual maturity rating (SMR)



Backgrounder – Beta Cell Proliferation

Beta Cells Proliferate during Pregnancy

British Journal of Obstetrics and Gynaecology
November 1978. Vol. 85. pp 818-820

A MORPHOLOGICAL STUDY OF THE ENDOCRINE PANCREAS IN HUMAN PREGNANCY

BY

F. A. VAN ASSCHE

L. AERTS

AND

F. DE PRINS

The Unit for the Study of Reproduction, Department of Obstetrics and Gynaecology, Academisch Ziekenhuis St Rafaël (KUL), Capucijnenvoer 35, 3000 Leuven, Belgium

Summary

During human pregnancy an enlargement of the islets of Langerhans and hyperplasia of the beta cells are present. These morphological changes indicate that the beta cells adapt to the metabolic changes of pregnancy.

"This quantitative morphological study shows a marked enlargement of the islets of Langerhans in pregnant women."

F. A. Van Assche et al. British Jornal of Obstetrics and Gynaecology, 1978 November

REFERENCES (continued)
Sternberg (1972); Taylor, 1972; Van Assche, 1974; Aerts and Van Assche, 1975), but no morphological studies have been made in human pregnancy since the early work of Rosenlöcker (1932). The recent introduction of more specific staining techniques for the study of the endocrine pancreas has enabled us to undertake a quantitative morphological study of the endocrine pancreas in the pregnant woman.

MATERIAL AND METHODS

Over many years we have been able to collect five pancreases from women who died during pregnancy or on the day of delivery; none of these women was overweight. The pancreases of

five women of comparable age, who died in car accidents and were not using oral contraceptives, were used as controls.

A sixth case is included, for interest, of a woman who died of post-molar choriocarcinoma. The clinical data are shown in Table I. A biopsy of the pancreatic tail was taken within 24 hours of death and fixed in Bouin's solution for 48 hours.

Sections of 3 µm thickness were made from paraffin embedded tissue. The slides were stained with haematoxylin-eosin and by Ivic's Victoria blue acid fuchsin method (Ivic, 1959) for the demonstration of the endocrine tissue and for the insulin producing β cells.

The ratio of endocrine to exocrine plus connective tissue was calculated by the morphometric method of Chalkley (1943).

For the percentage of β cells, 2000 cells were counted with the nucleus as a counting base.

RESULTS

From Table II it is clear that the amount of endocrine tissue and also the percentage of β

Participation of Akt, Menin, and p21 in Pregnancy-Induced β-Cell Proliferation

Elizabeth Hughes and Carol Huang

University of Calgary, Faculty of Medicine, Departments of Pediatrics and Biochemistry and Molecular Biology, Calgary, Alberta, Canada T2N 4N1

β-Cell mass increases during pregnancy to accommodate for insulin resistance. This increase is mainly due to β-cell proliferation, a process that requires intact prolactin receptor (Prlr) signaling. Signaling molecules that are known to regulate β-cell proliferation include Jak2, Akt, the tumor suppressor menin, and cell cycle proteins. Whether these pathways are involved in prolactin-mediated β-cell proliferation is unknown. Using the heterozygous prolactin receptor-null (*Prlr*^{+/-}) mice, we isolated pancreatic islets from both *Prlr*^{+/-} and *Prlr*^{+/-} mice on d 0 and 15 of pregnancy and examined the expression levels of these signaling molecules. In the wild-type mice (*Prlr*^{+/-}), both phospho-Jak2 and phospho-Akt expression in pancreatic islets increased during pregnancy, which were attenuated in the pregnant *Prlr*^{+/-} mice. During pregnancy, menin expression was reduced by 50 and 20% in the *Prlr*^{+/-} and the *Prlr*^{+/-} mice, respectively, and the pregnant *Prlr*^{+/-} mice had higher islet p18 levels than *Prlr*^{+/-} mice. Interestingly, between d 0 and 15 of pregnancy, expression of cyclin D1 and cyclin E1 increased in the *Prlr*^{+/-} mice, but this increase

Downloaded from https://academic.oup.com/endo/article/152/3/847/2553333/full by guest on 25 May 2023

"We conclude that during pregnancy, placental hormones act through the prolactin receptor to increase beta cell mass by up regulating beta cell proliferation by engaging Jak2, Akt, menin/p18, and p21."

Hughes et al. Endocrinology, March 2011, 152(3):847–855

We found that transgenic mice with heterozygous deletion of the prolactin receptor (*Prlr*^{+/-}) have impaired glucose tolerance during pregnancy but normal glucose homeostasis during the nonpregnant state. In addition, the pregnant *Prlr*^{+/-} mice have lower serum insulin levels in comparison with the *Prlr*^{+/-} mice, which correlated with a reduced β-cell mass and a decreased β-cell proliferation rate in the pregnant *Prlr*^{+/-} mice. These results suggest that during pregnancy, the action of pregnancy hormones is essential for maintaining adequate insulin responses by enhancing β-cell proliferation, thereby increasing β-cell mass.


Abbreviations: CDK, Cyclin-dependent kinase; CIP, cyclin inhibitory protein; IR, insulin receptor; IRS, IR substrate; PI3K, phosphoinositide-3-kinase.

Background – Beta Cell Proliferation

Beta Cells Proliferate During Pregnancy and Stay Elevated Thereafter


TABLE II <i>The endocrine pancreas in non-pregnant and pregnant women</i>		
	Endocrine tissue (per cent)	β cells (per cent)
<i>Non-pregnant women</i>		
1	1·6	75
2	1·5	68
3	2·0	78
4	1·4	69
5	1·3	74
Mean ± SD	1·56 ± 0·27	72·8 ± 4·2
<i>Pregnant women</i>		
1	3·2	81
2	3·1	83
3	2·9	79
4	3·6	84
5	3·7	83
Mean ± SD	3·3 ± 0·3	82·0 ± 1·8
P	<0·001	<0·005

Assche and Aerts.
British Journal of Obstetrics and Gynaecology. 1978



Butler et al. *Diabetologia.* 2010


Lactation Duration Showed a Strong, Graded Inverse Association with Diabetes Incidence



Among young white and black women in this observational 30-year study*, increasing lactation duration was associated with a strong, graded 25% to 47% relative reduction in the incidence of diabetes even after accounting for prepregnancy biochemical measures, clinical and demographic risk factors, gestational diabetes, lifestyle behaviors, and weight gain.



Backgrounder – Beta Cell Proliferation

Beta Cells Proliferate in Obesity





Backgrounder – Beta Cell Proliferation

Beta Cell Mass and Volume Expands with Obesity



β -cell volume is 20-50% higher in
Obese humans without diabetes




Rahier et al. *Diabetes Obes Metab*. 2008 4:32-42

Saisho Y et al, *Diabetes care*, August 2012

Backgrounder – Beta Cell Proliferation

Beta Cells Replicate

There are Local and Circulating Factors that support Beta Cell Replication



Dr. Kim, S.K. et al., *Science*. 2007 Nov 2. doi: 10.1126/science.1146812.; Linnemann et al. *American Society for Nutrition. Adv. Nutr.* 5: 278–288, 2014; F. A. Van Assche et al. *British Journal of Obstetrics and Gynaecology*, 1978 November; Hughs et al. *Endocrinology*, March 2011, 152(3):847–855

Beta Cell Proliferation


- Validation from Preclinical Results of BMF-219

Backgrounder – Beta Cell Proliferation


BMF-219 increases β -islets in pancreas sections of ZDF diabetic model

as presented during EASD 2022


A. Vehicle; Day 31




B. Pioglitazone; Day 17



D. BMF-219; Day 31



C. BMF-219; Day 17




A) Vehicle-treated animal, Day 31. Beta islets display low congregation and growth, while alpha cells dominate. **B)** Pioglitazone-treated animal, Day 17. Beta islets display congregation and growth. **C)** BMF-219 treated animal, Day 17. In contrast to the pioglitazone-treated animal shown in Panel B, note that BMF-219 treatment results in high congregation and growth of the beta islets. **D)** BMF-219 treated animal, Day 31. Beta islets display high congregation and continue to increase and mature. Red is insulin-beta islets, brown is glucagon-alpha cells.

Backgrounder – Beta Cell Proliferation

Human Donor Islets (Ex-Vivo) Statistically Significant Increase Beta Cells with BMF-219

as presented during EASD 2022



Beta Cell Proliferation

- Literature References

Backgrounder – Beta Cell Proliferation

Relevant Literature

- [**Pancreatic β-cell proliferation in obesity**](#) Linnemann AK, Baan M, Davis DB Advances in Nutrition – 2014 May 14, 5(3):278-88. doi: 10.3945/an.113.005488. PMID: 24829474; PMCID: PMC4013180.
- [**A morphological study of the endocrine pancreas in human pregnancy**](#) F.A. Van Assche FA, L. Aerts L, F. De Prins British Journal of Obstet Gynaecology – 1978 Nov, 85(11):818-20. doi: 10.1111/j.1471-0528.1978.tb15835.x. PMID: 363135.
- [**Beta cell adaptation to pregnancy requires prolactin action on both beta and non-beta cells**](#) Shrivastava V, Lee M, Lee D, Pretorius M, Radford B, Makkar G, Huang C. Scientific Reports – 2021 May 14, 11(1):10372. doi: 10.1038/s41598-021-89745-9. PMID: 33990661; PMCID: PMC8121891.
- [**Prolactin-regulated Pbk is involved in pregnancy-induced β-cell proliferation in mice**](#) Cao, Y., Feng, Z., He, X., Zhang, X., Xing, B., Wu, Y., Hojnacki, T., Katona, B. W., Ma, J., Zhan, X., & Hua, X. (2022) *Journal of Endocrinology*, 252(2), 107-123.
- [**Expansion of β-cell mass in response to pregnancy**](#) Sebastian Rieck and Klaus H. Kaestner Trends in Endocrinology and Metabolism – 2010, Mar 21, (3):151-8. doi: 10.1016/j.tem.2009.11.001. Epub 2009 Dec 16.
- [**Beta-cell compensation and gestational diabetes**](#) Taofeek O Usman, Goma Chhetri, Hsuan Yeh, H Henry Dong *Journal of Biological Chemistry* – 2023, Dec, 299(12):105405. doi: 10.1016/j.jbc.2023.105405. Epub 2023 Oct 29.
- [**Serum from pregnant donors induces human beta cell proliferation and insulin secretion**](#) Sylvester-Armstrong KR et al. *bioRxiv* – 2023, Apr 17, 2023.04.17.537214. doi: 10.1101/2023.04.17.537214
- [**Modulatory role of prolactin in type 1 diabetes**](#) Ramos-Martínez E et al. *Hormone Molecular Biology and Clinical Investigation* – 2022, Jul 19, 44(1):79-88. doi: 10.1515/hmbci-2022-0008. eCollection 2023 Mar 1.
- [**Pancreatic islet cell type-specific transcriptomic changes during pregnancy and postpartum**](#) Chung J-Y et al. *iScience* – 2023 Mar 17, 26(4):106439. doi: 10.1016/j.isci.2023.106439. eCollection 2023 Apr 21.
- [**Breastfeeding can reduce the risk of developing diabetes**](#) Soo Young Kim *Korean Journal of Family Medicine* – 2018, 39(5):271-272. Published online: September 20, 2018 DOI: <https://doi.org/10.4082/kjfm.39.5E>
- [**Potential protective effect of lactation against incidence of type 2 diabetes mellitus in women with previous gestational diabetes mellitus**](#) Tanase-Nakao K et al. *Diabetes Metab Res Review* – 2017 May, 33(4): e2875. Published online 2017 Feb 23. doi: 10.1002/dmrr.2875
- [**Lactation and progression to type 2 diabetes in patients with gestational diabetes mellitus – A systematic review and meta-analysis of cohort studies**](#) Feng L et al. *Journal of Diabetes Investigation* – 2018 Nov 9, (6):1360-1369. doi: 10.1111/jdi.12838. Epub 2018 Apr 18.
- [**Lactation and progression to Type 2 diabetes mellitus after gestational diabetes mellitus – A prospective cohort study**](#) Gunderson EP et al. *Annals of Internal Medicine* – 2015 Dec 15, 163(12):889-98. doi: 10.7326/M15-0807. Epub 2015 Nov 24.
- [**Prior lactation reduces future diabetic risk sustained postweaning effects on insulin sensitivity**](#) Bajaj H et al. *American Journal of Physiology: Endocrinology and Metabolism* – 2017 Mar 1, 312(3):E215-E223. doi: 0.1152/ajpendo.00403.2016. Epub 2016 Dec 13.
- [**Association of lactation with maternal risk of type 2 diabetes – A systematic review and meta-analysis of observational studies**](#) Pinho-Gomes A-C et al. *Diabetes, Obesity and Metabolism* – 2021 Aug, 23(8):1902-1916. doi: 10.1111/dom.14417. Epub 2021 May 20.
- [**Lactation duration and progression to diabetes in women across the childbearing years – The 30-year CARDIA study**](#) Gunderson EP et al. *JAMA Internal Medicine* – 2018 Mar, 178(3): 328–337. Published online 2018 Jan 16. doi: 10.1001/jamainternmed.2017.7978
- [**Effect of breastfeeding and its duration on impaired fasting glucose and diabetes in perimenopausal and postmenopausal women – Korea National Health and Nutrition Examination Survey \(KNHANES\)**](#) Kwan B-S et al. *Medicines* – 2021 Nov 12, 8(11):71. doi: 10.3390/medicines8110071.

Contact:

Chunyi Zhao, PhD

Associate Director of Investor Relations & Corporate Development

czhao@biomeafusion.com

T: +1 650-460-7759

THANK YOU



We Aim to Cure™

Biomea Fusion

900 Middlefield Road, 4th floor

Redwood City, CA, 94063

biomeafusion.com

